ChromaGenix, an NC State spinout, launched a commercial platform built around synthetic peptide ligands for purifying viral vectors used in gene therapies and other biologic manufacturing. The company positions peptides as an alternative to protein ligands in affinity chromatography, citing lower cost and reduced immunogenicity risk as production constraints. Management also argues peptides can withstand harsh cleaning conditions longer than protein ligands and may improve recoverability when products bind too strongly in traditional chromatographic steps. The pitch extends beyond gene therapies: ChromaGenix said its roadmap targets purification of therapeutic cells such as CAR T. For the gene therapy supply chain, the development matters because downstream purification is a recurring bottleneck that impacts yield, batch consistency, and overall manufacturing economics.